52 results about "Sodium taurocholate" patented technology

The invention provides a liposome injection of a pharmaceutical composition of amoxicillin sodium and clavulanate potassium, which consists of amoxicillin sodium, clavulanate potassium, a liposome carrier, a lyoprotectant and a freely optional antioxidant, wherein the liposome carrier is egg yolk phosphatidylinositol and sodium taurocholate. The liposome injection has good preparation stability, liposome can avoid the fracture due to dehydration, fusion, ice crystal generation and the like during the freeze-drying process, and the liposome can still keep the good encapsulation rate after hydration and redissolution.

The invention discloses a collagen skin firming lifting plumping glowing cream which comprises red ginseng snail secreta filter liquor, soluble collagen, hydrolysis collagen, atelocollagen, sodium hyaluronate, caesalpinia spinosa fruit extracts/Kappaphycus alvarezii extracts, nicotinamide, mica, hydrogenated phosphatidylcholine, lysoph-osphatidylcholine/sclerotium gum/xanthan gum/aureobasidium pullulans polysaccharide, mentha piperita extracts, hydroxyethyl acrylate/acryloyl dimethyl sodium taurocholate copolymers. Periocular skins are firmed, lifted and glowed from outside to inside by the aid of the cream. Ray refraction modes are adjusted by the aid of the mica, so that wrinkles are flatted, skins are brightened, melanin can be restrained by the nicotinamide, black eyes are faded, 'external regulation and internal nourishing' are achieved, the periocular skins are rapidly and effectively brightened and rapidly firmed and lifted, the hydrogenated phosphatidylcholine serves as emulsifying agents and thickening agents, mild and non-irritating effect is achieved, the mentha piperita extracts bring cool and refreshing skin feeling, fatigue is relieved, generation of fat granules is prevented, and the healthy state of the skins is kept.

The present invention discloses a tauroursodeoxycholic acid synthesis method, which comprises that chenodeoxycholic acid is adopted as a raw material, the chenodeoxycholic acid and N-hydroxy succinimide or N-hydroxyphthalimide are subjected to condensation under effects of a condensation agent and a catalyst to obtain an active ester, the active ester reacts with sodium taurocholate to obtain taurochenodeoxycholic acid, and further an oxidation reaction and a reduction reaction are performed to synthesize the tauroursodeoxycholic acid. The synthesis method of the present invention adopts the chenodeoxycholic acid as the raw material, and has characteristics of low cost, simple and controllable purification process, high target product purity, and easy industrialization.

The invention discloses a synthesis method of N-methyl-N-(4,6-aliphatic fatty diamine-1,3,5-s-triazine-2-group)-2-amino sodium taurine amphoteric surfactants which are prepared from cyanuric chloride, alicyclic amine and N-methyl sodium taurocholate as main raw materials. The synthesis method comprises the following steps of: dissolving the cyanuric chloride into acetone or ethanol, dropping alicyclic amine A at the temperature of 0-5DEG C and using an alkaline solution as an acid binding agent; dissolving the purified 2-fatty amine-4,6-dichlone-1,3,5-s-triazine into an acetone solution and reacting with a water solution of 40 percent N-methyl sodium taurocholate at the temperature of 30-50DEG C to generate N-methyl-N-(4-fatty amine-6-chloride-1,3,5-s-triazine-2-group)-2-amino sodium taurine amphoteric surfactants; condensing at reduced pressure, sucking filtering and vacuum drying; and dissolving the obtained N-methyl-N-(4-fatty amine-6-chloride-1,3,5-s-triazine-2-group)-2-amino sodium taurine amphoteric surfactants into a mixed solution of ethanol and water and reacting with licyclic amine B at the temperature of 80-100DEG C to obtain the N-methyl-N-(4,6-aliphatic fatty diamine-1,3,5-s-triazine-2-group)-2-amino sodium taurine amphoteric surfactants. The synthesis method is simple; the yield in each step of reaction is more than or equal to 80.00 percent; the solvents for reaction include petroleum ether, ethyl acetate, acetone, ethanol and water and have little hazard to human body; and the petroleum ether and the ethyl acetate can be recycled and are environment-friendly.

The invention relates to an irbesartan-hydrochlorothiazide drug combination liposome solid preparation, which is prepared with irbesartan-hydrochlorothiazide drug combination liposome and other solid preparation auxiliary materials, and the irbesartan-hydrochlorothiazide drug combination liposome is prepared with irbesartan, hydrochlorothiazide, distearoyl phosphatidylcholine and sodium taurocholate. Compared with the conventional preparation, the stability and bioavailability of the preparation are greatly enhanced, release is stable, the side effect is minor, and the treatment effect is more remarkable.

The invention provides a Chinese medicine composition used for curing coronary heart disease, angina, arrhythmia and high blood fat and a preparation method thereof. The Chinese medicine composition consists of components as follows: 5 to 20 weight percentage of musk, 12 to 50 weight percentage, 60 to 250 weight percentage of sodium taurocholate, 12 to 50 weight percentage of toad venom, 30 to 120 weight percentage of pearl, 40 to 160 weight percentage of borneol, 1500 to 15000 weight percentage of panax pseudo-ginseng wallich, 150 to 600 weight percentage of ginseng and 50 to 200 weight percentage of the dry extract of buffalo horn. The Chinese medicine composition of the invention can improve blood circulation, dilate coronary arteries, enhance myocardial ischemia, decrease crown arteries resistance, regulate cardiac rate, lower blood pressure, reduce myocardium metabolism, decrease consumed oxygen of myocardium and relieve or eliminate angina via the synergistic and beneficial antagonistic effect of the medicine. As a great amount of the sodium taurochlate is adopted, product cost is reduced while drug effect is ensured as much as possible, thus reducing the economic burden of a patient.

Disclosed is a method for preparing insulin oral formulation which comprises, (1) dissolving acrylic resin III in anhydrous alcohol solution, obtaining solution A, (2) charging insulin into the solution A to obtain solution B, (3) dissolving sodium taurocholate in liquid paraffin, charging into solution B to obtain solution C, (4) dissolving gelatin into distilled water, charging into solution C to obtain a first enveloped insulin microballoons, which is called solution D, (5) charging equal amount of fluid wax with solution C into solution D to obtain solution E, (6) dissolving acetylsalicylic acid into distilled water to form miscible liquid, charging equal amount of miscible liquid of gelatin and distilled water into another solution A, charging into solution E, finally obtaining a second enveloped insulin microballoon solution.

This application relates to a homogeneous biorelevant composition for preparing fasted state biorelevant media having a surface tension between 25 mN/m and 50 mN/m for simulating fasted state gastric and fasted state upper small intestinal fluids of mammalian species, especially humans, dogs, etc. comprising at least one bile salt, eg. sodium taurocholate or sodium taurodeoxycholate; at least one phospholipid, especially 60-99 wt % phosphatidylcholine (PC), enzyme digested diacylphospholipids containing 50-90 wt % of monoacyl-PC; or mixtures thereof; and at least one fatty acid or monovalent salt of the fatty acid, such as sodium oleate. The application also relates to an aqueous biorelevant media composed of surfactants occurring in the gastrointestinal tract of mammals, in particular when prepared from above homogeneous biorelevant composition.

The invention discloses an injection dihydroartemisinin emulsion, which is prepared by adjusting the pH value of the mixture consisting of the following raw materials with weight/volume percent based on the total volume of the emulsion: 0.05-0.3 percent of dihydroartemisinin, 5-30 percent of injection oil, 0.5-10 percent of emulsion, 0.1-3 percent of stabilizing agent, 0.5-5 percent of isoosmotic adjustment agent and the rest of injection water; the stabilizing agent consists of one or more of sodium taurocholate, sodium deoxycholate, oleic acid, sodium oleate and cholesterin and glycerol stearate. Freeze-dried emulsion can be made through freeze drying after adding freeze-dried protecting agent into the emulsion. The invention also discloses a method for preparing the emulsion as well as the freeze-dried emulsion. The injection dihydroartemisinin emulsion prepared by the method leads to the stable existence of dihydroartemisinin in the oil phase of the emulsion and has the advantages of good long term stability and curative effect, high bioavailability and accordance with the standards of intravenous injection; and the freeze-dried emulsion is convenient for carrying and storage and can further increase the stability of drugs.

The invention provides an oral insulin composition. The composition comprises the following components in parts by weight: 1 part of insulin, 0.01-0.05 part of sodium glycocholate, 10-50 parts of sodium taurocholate, 130-150 parts of lecithin, 0.5-5 parts of cholesterol, 1-1.5 parts of bilirubin, 0.01-0.1 part of chloroquine, 10-50 parts of microcrystalline cellulose, and 2-5 parts of gelatin. The invention also provides a preparation method of the oral insulin composition. The duration time of insulin reaches 3 days or above due to the oral insulin composition, and at the same time, compared with saled long-acting insulin, the composition has better hypoglycemic effects.

The invention discloses repair nourishing creamy essential oil handmade soap which comprises, by weight, 24-28 parts of methyl lauroyl sodium taurocholate, 10-15 parts of octadecyl sulfopropyl glycine betaine, 53-56 parts of vegetable oil, 2-3 parts of vegetable glycerin, 12-15 parts of hyaluronic acid, 4-8 parts of glutathione, 0.7-1 part of endothelial cell growth factors, 9-12 parts of goat milk, 4-6 parts of royal jelly, 1-2 parts of vitamin, 2.5-4 parts of 1, 2-propanediol, 1.5-2.5 parts of hydroxyethyl urea, 1-1.5 parts of sodium lactate, 1-2 parts of menthol, 2-3 parts of pachymaran, 5-8 parts of astragalus polysaccharide, 2-4 parts of salvia extract and 6-8 parts of plant essential oil. The repair nourishing creamy essential oil handmade soap is mild and clear and has the functions of delaying skin aging, decreasing melanogenesis, enabling skins to be fair, clear and delicate, achieving plentiful nourishing and efficient uptake, repairing injured cells, promoting cell metabolism, preserving moisture, whitening and enhancing external injury resistance of the skins.

The invention discloses a construction method of a pancreatic duct epithelial cell and pancreatic acinar cell co-culture system for simulating in vivo microenvironment, and belongs to the technical field of cell biology. The method comprises the steps of inoculating an upper layer of a Transwell dual-layer culturing chamber with original generation pancreatic acinar cells, inoculating a lower layer of the Transwell dual-layer culturing chamber with human pancreatic duct epithelial cells, performing co-culturing, adding sodium taurocholate in the pancreatic duct epithelial cells at the lower layer of the Transwell dual-layer culturing chamber, and observing the vitality, the shape and the apoptosis of the upper layer pancreatic acinar cells. Damage of the pancreatic duct epithelial cells and the pancreatic acinar cells are combined, a non-contact type co-culture manner is adopted for building the pancreatic duct epithelial cell and pancreatic acinar cell co-culture system. In the co-culture system, the two cells can exchange exocytosis secretion substances through Transwell transmembrane. The system can well simulate the pancreatitis induced by cholestasis, and the invention provides an in vitro cell model which can really reflect pancreatitis induced by cholestasis.

The invention belongs to the foodstuff and health product field, in particular relates to an application of the traditional Chinese medicine of medlar and blackfungus to the preparation of a drug for curing fatty liver. The invention adopts a medlar and blackfungus compound granular formulation. The fat emulsion made of fat, cholesterin, sodium taurocholate and propylthiouracil is given to rats; a fatty liver animal model is made; the function for preventing fatty liver of medlar and blackfungus is studied. The experimental results show that the medlar and the blackfungus have evident functions for preventing fatty liver and can reduce the liver weight/body mass index, the contents of serum and hepatic tissue cholesterin are decreased and the number of liver cells of steatosis is reduced. The medlar and the blackfungus can be used for preparing the drug for curing fatty liver.

The invention discloses a refining method for sodium taurocholate. The method includes the following steps that a crude sodium taurocholate product is dissolved in alcoholic solvents, ester solvents are added while the alcoholic solvents are hot, after cooling, the temperature is reduced, and high-purity sodium taurocholate is obtained by vacuum drying. Compared with the prior art, the method hasthe advantages that the refining method is simple in operation, ester solvents with relatively higher boiling points are adopted to reduce solvent volatilization, thus use of acetone with irritating odor and the use of low-boiling-point ether are avoided, operation is safer, and industrial production is facilitated. The yield is high, the product purity is high and not less than 91%, the purity ofrefined sodium taurocholate is 100% through an area normalization method, the purity of HPLC is more than and equal to 99.00% through ELSD detection, the purity of HPLC can be up to 99.91%, the content of a single impurity A is smaller than 0.30%, the content of a single impurity B is smaller than 0.8%, the type of impurities is significantly reduced, and the refined final product are free of impurities C and D.

The invention discloses a nursing medicine for preventing liver injury postoperation complications and a preparation method thereof. The nursing medicine for preventing liver injury postoperation complications is prepared from, by weight, raffinose, betulinic acid, naringenin, cryptotanshinone, nutritional nano powder, paulownia leaf extracts, extracts of herb of Wilson wassionflower, beautyberry leaf extracts, sodium taurocholate, alpinetin, riboflavin, vitamin A and amino acid. By means of reasonable matching of various components, the nursing medicine has the effects of promoting blood circulation to remove stasis, cooling the blood to stop bleeding, diminishing inflammation to relieve pain and being anti-microbial and anti-infectious, meanwhile, nutrients needed by a human body after an operation are supplemented, immunity is improved, side effects caused by Western medicine are reduced, the nursing medicine is used for nursing liver injury postoperation complications, and the curative effect is remarkable.

The invention discloses a novel method for detecting a taurocholic acid content and related substances. The method comprises the following steps: taking a taurocholic acid-TRC reference substance as aknown reference substance, dissolving the reference substance by a diluent to form a reference substance solution, and dissolving a taurocholic acid sample by a diluent to form a reference substancesample solution; injecting 20ul of each solution into a liquid chromatograph respectively, recording a peak area, and carrying out calculation according to an external standard method on the basis ofanhydrous taurocholic acid; taking cholic acid as a reference substance, dissolving the reference substance by a mobile phase to form a concentration impurity reference substance solution, and dissolving the taurocholic acid sample by a diluent to form a concentration sample solution; injecting 20ul of each solution into the liquid chromatograph respectively, recording the peak areas of sodium taurocholate and cholic acid in a chromatogram, and calculating the sizes of related substances in the taurocholic acid sample according to the external standard method. Effective separation and accuratequantitative detection of taurochenodeoxycholic acid and chenodeoxycholic acid which are two cholic acid substances with large difference in polarities are realized under the same liquid chromatography condition.

The slow released antituberculotic preparation contains the composition of ofloxacin, ciprofloxacin or sparxacin, capreomycin, sodium taurocholate and/or deoxysodium taurocholate. The slow released antituberculotic preparation is slow released injection or slow released implanting agent. The injection consists of slow released microsphere and solvent. The slow released microsphere contains slow releasing supplementary material and antituberculotic and the solvent is special solvent containing suspending agent carboxymethyl cellulose, etc. and with viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released implanting agent is prepared through a certain process. The present invention has obvious unique treating effect on various kinds of intractable tuberulosis.

The present invention provides a carbon black particle dispersing agent, a preparation method and an application thereof. The carbon black particle dispersing agent is formed by mixing sodium dodecylbenzene sulfonate and/or sodium taurocholate, ethylene glycol and an organic solvent. With the carbon black particle dispersing agent, the dispersion of the carbon black aggregate can achieve the small state, the number of the carbon black particles in each aggregate is less, and the guarantee can be provided for the quality of the polyethylene mixing material. The carbon black particle dispersing agent can be used for preparation of high performance polyethylene pipes.

The invention discloses a myrtle polysaccharide P4, a separation and purification method thereof and an application of the polysaccharide P4 to preparation of a blood-lipid lowering drug. The polysaccharide comprises, in mole percent, 10.48% of monosaccharide: ribose, 4.05% of rhamnose, 65.50% of arabinose, 5.13% of xylose, 2.39% of mannose, 4.74% of glucose and 7.71% of galactose. Experimental results indicate that the myrtle polysaccharide P4 has a certain in-vitro cholate binding capacity, colestyramine serves as a positive control, and relative binding rates of the myrtle polysaccharide P4for sodium taurocholate, sodium glycocholate and sodium cholate are 31.54%, 47.61% and 52.76% by transformation according to the binding rate of 100% of the colestyramine for cholate.

The invention discloses myrtle polysaccharide P3, a separation method thereof and application of the myrtle polysaccharide P3 in blood-lipid-lowering drugs. The myrtle polysaccharide P3 comprises, bymole percentage, 9.97% of ribose, 2.40% of rhamnose, 64.51% of arabinose, 6.14% of xylose, 5.39% of mannose, 1.74% of glucose and 9.85% of galactose. Experiment results show that the myrtle polysaccharide P3 has certain in-vitro cholate binding ability; when colestyramine is used as the positive control and the cholate binding rate of the colestyramine is 100%, the sodium taurocholate relative binding rate of the myrtle polysaccharide P3 is 29.65%, the sodium glycocholate relative binding rate of the myrtle polysaccharide P3 is 45.84%, and the sodium cholate relative binding rate of the myrtlepolysaccharide P3 is 51.90%.